Clearmind Medicine Begins Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder

Novel psychedelic-derived treatment targeting Alcohol Use Disorder (AUD). The trial is now active at all planned sites, including Yale School of Medicine, Johns Hopkins University School of Medicine, and the IMCA Center in Israel. This milestone follows the company's completion of all necessary preparations, such as obtaining FDA Investigational New Drug (IND) approval, securing Institutional Review Board (IRB) approvals, launching an Electronic Data Capture (EDC) system, and successfully manufacturing and importing CMND-100 into the United States. 

The study, led by Dr. Anahita Bassir Nia at Yale and Dr. Eric Strain at Johns Hopkins, aims to evaluate the safety, tolerability, and pharmacokinetics of CMND-100 in humans. Additionally, it will assess preliminary efficacy in reducing alcohol cravings and consumption. CMND-100, based on Clearmind's proprietary MEAI platform, represents a pioneering approach in addressing the neurobiological aspects of AUD, potentially offering a new avenue for treatment where current therapies often fall short. 

Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine, emphasized the significance of this development, stating, "With millions affected and current treatments often falling short, the study initiation for our FDA-approved CMND-100 trial marks a critical step toward potentially transforming the treatment landscape for alcoholism." The company's collaboration with esteemed institutions like Yale and Johns Hopkins underscores its commitment to advancing innovative solutions for individuals suffering from alcoholism.